{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:53:42Z","timestamp":1790481222438,"version":"4.1.0"},"reference-count":106,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,27]]},"DOI":"10.18632\/oncotarget.7043","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T03:44:32Z","timestamp":1453952672000},"page":"64431-64446","source":"Crossref","is-referenced-by-count":162,"title":["Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer"],"prefix":"10.18632","volume":"7","author":[{"given":"Debora","family":"de Melo Gagliato","sequence":"first","affiliation":[{"name":"Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Leonardo Fontes Jardim","sequence":"additional","affiliation":[{"name":"Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Sergio Pereira","family":"Marchesi","sequence":"additional","affiliation":[{"name":"Roche Pharmaceuticals, S\u00e3o Paulo SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"issue":"1","key":"1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3322\/caac.21203","article-title":"Breast cancer statistics, 2013","volume":"64","author":"Jemal","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Cannady","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"4785","key":"3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"McGuire","year":"1987","journal-title":"Science"},{"issue":"6","key":"4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/bcr327","article-title":"Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2\/HER-2 and family members","volume":"3","author":"Olayioye","year":"2001","journal-title":"Breast Cancer Res"},{"issue":"Suppl 1","key":"5","first-page":"S3","article-title":"The basic biology of HER2","volume":"12","author":"Yarden","year":"2001","journal-title":"Ann Oncol"},{"issue":"1","key":"6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"26","key":"7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Davidson","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Norton","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Slamon","year":"1999","journal-title":"J Clin Oncol"},{"key":"10","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"D'Amico","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"33","key":"11","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Davidson","year":"2014","journal-title":"J Clin Oncol"},{"key":"12","article-title":"A phase II study of adjuvant paclitaxel and trastuzumab (APT) trial for node-negative, HER2-positive breast cancer","author":"Winer","year":"2013","journal-title":"2013 San Antonio Breast Cancer Symposium"},{"issue":"2","key":"13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Ross","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Benyunes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Benyunes","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"16","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to Trastuzumab in Breast Cancer","volume":"15","author":"Mernaugh","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"23","key":"17","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Brugge","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Yu","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"van de Vijver","year":"2007","journal-title":"Cancer Cell"},{"issue":"24","key":"20","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","article-title":"Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer","volume":"18","author":"King","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jnci\/djt121","article-title":"Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer","volume":"105","author":"Sotiriou","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1185\/03007995.2013.794775","article-title":"The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis","volume":"29","author":"Lu","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.2014.56.2439","article-title":"Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial","volume":"33","author":"Geyer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"24","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2012.42.2642","article-title":"Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial","volume":"31","author":"Harris","year":"2013","journal-title":"J Clin Oncol"},{"key":"25","article-title":"Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer","author":"Mark","year":"2013","journal-title":"AACR Annual Meeting"},{"issue":"2","key":"26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Wang","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"23","author":"Crown","year":"2012","journal-title":"Ann Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Matera","year":"2008","journal-title":"J Transl Med"},{"issue":"33","key":"29","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Swain","year":"2014","journal-title":"J Clin Oncol"},{"key":"30","article-title":"PIK3CA Mutation Predicts Resistance to Anti-HER2\/Chemotherapy in Primary HER2-Positive\/Hormone-Receptor-Positive Breast Cancer - Prospective Analysis of 737 Participants of the GeparSixto and GeparQuinto Studies","author":"von Minckwitz","year":"2013","journal-title":"San Antonio Breast Cancer Annual Meeting (San Antonio, Tx)"},{"issue":"29","key":"31","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Huober","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"32","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr3690","article-title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","volume":"16","author":"Cortes","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"12","key":"33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer","volume":"33","author":"de la Pena","year":"2015","journal-title":"J Clin Oncol"},{"key":"34","first-page":"511","article-title":"Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials","volume":"33","author":"Conte","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"issue":"6","key":"35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Lang","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Toi","year":"2015","journal-title":"Lancet Oncol"},{"key":"37","article-title":"Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer","author":"Slamon","year":"2014","journal-title":"San Antonio Breast Cancer Symposium (San Antonio, Tx)"},{"key":"38","first-page":"512","article-title":"Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3","volume":"33","author":"Riester","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"39","volume-title":"ESMO","author":"Chen","year":"2013"},{"key":"40","first-page":"LBA509","article-title":"Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2","volume":"31","author":"Anderson","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"6","key":"41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Yardley","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"42","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-13-1070","article-title":"Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy","volume":"20","author":"Sternberg","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-014-3248-4","article-title":"Phase I\/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer","volume":"149","author":"Winer","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"44","first-page":"590","article-title":"Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)","volume":"33","author":"Fornier","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"issue":"5","key":"45","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-10-3795","article-title":"p95HER2 and breast cancer","volume":"71","author":"Parra-Palau","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Baselga","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1078-0432.CCR-05-1807","article-title":"p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer","volume":"12","author":"Clinton","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"16","key":"48","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","article-title":"Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients","volume":"16","author":"Kostler","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-013-2665-0","article-title":"HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer","volume":"141","author":"Paquet","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"50","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/MCB.01803-08","article-title":"A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis","volume":"29","author":"Arribas","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"11","key":"51","article-title":"Effect of p95HER2\/611CTF on the response to trastuzumab and chemotherapy","volume":"106","author":"Baselga","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"52","volume-title":"36th San Antonio Breast Cancer Symposium","author":"Baselga","year":"2013"},{"issue":"24","key":"53","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Pollak","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"54","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/1535-7163.MCT-05-0048","article-title":"Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody","volume":"4","author":"Greenberg","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"55","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Esteva","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"56","first-page":"BR521","article-title":"Co-targeting HER2\/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells","volume":"8","author":"Pollak","year":"2002","journal-title":"Med Sci Monit"},{"issue":"1","key":"57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/annonc\/mdq349","article-title":"Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells","volume":"22","author":"O'Donovan","year":"2011","journal-title":"Ann Oncol"},{"issue":"4995","key":"58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product","volume":"251","author":"Aaronson","year":"1991","journal-title":"Science"},{"issue":"8","key":"59","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: a MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Comoglio","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"60","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.2011.40.3774","article-title":"Targeting the hepatocyte growth factor-cMET axis in cancer therapy","volume":"30","author":"Gonzalez-Angulo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E","article-title":"Expression of the c-Met\/HGF receptor in human breast carcinoma: correlation with tumor progression","volume":"74","author":"Kramer","year":"1997","journal-title":"Int J Cancer"},{"issue":"4","key":"62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.20598","article-title":"C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/neu","volume":"113","author":"Harbeck","year":"2005","journal-title":"Int J Cancer"},{"issue":"8","key":"63","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-11-2830","article-title":"cMET and phospho-cMET protein levels in breast cancers and survival outcomes","volume":"18","author":"Gonzalez-Angulo","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2012.335","article-title":"Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer","volume":"107","author":"Zok","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"65","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","article-title":"Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells","volume":"68","author":"Sweeney","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"66","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/1535-7163.MCT-10-0698","article-title":"Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells","volume":"10","author":"Gilmer","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"67","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"68","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.2309","article-title":"Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways","volume":"17","author":"Hortobagyi","year":"2011","journal-title":"Nat Med"},{"issue":"4","key":"69","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bjc.2014.327","article-title":"Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma","volume":"111","author":"Lerma","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"70","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr3650","article-title":"Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models","volume":"16","author":"Parsons","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"21","key":"71","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1200\/JCO.2010.28.6922","article-title":"Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy","volume":"28","author":"Nuti","year":"2010","journal-title":"J Clin Oncol"},{"issue":"34","key":"72","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Pajunen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"73","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Denkert","year":"2014","journal-title":"Ann Oncol"},{"key":"74","first-page":"507","article-title":"Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial","volume":"30","author":"Joensuu","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"75","article-title":"Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study","author":"Pusztai","year":"2012","journal-title":"SABCS Annual Meeting Abstracts"},{"issue":"4","key":"76","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"77","article-title":"Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2- positive breast cancer (HER2+ BC)","author":"al","year":"2013","journal-title":"2013 San Antonio Breast Cancer Symposium"},{"issue":"7","key":"78","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2014.57.6298","article-title":"Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial","volume":"33","author":"McCullough","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-suppl_3-10","article-title":"Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR\/ErbB-2 inhibitor lapatinib","volume":"9","author":"Burris","year":"2004","journal-title":"Oncologist"},{"issue":"21","key":"80","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Wissner","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"81","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Florance","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"82","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Berger","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"83","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"O'shaughnessy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9816","key":"84","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Chang","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"85","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","volume":"14","author":"Brufsky","year":"2013","journal-title":"Lancet Oncol"},{"key":"86","first-page":"LBA4","article-title":"First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)","volume":"32","author":"Lang","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"issue":"6","key":"87","doi-asserted-by":"crossref","first-page":"e0129876","DOI":"10.1371\/journal.pone.0129876","article-title":"Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies","volume":"10","author":"Rubio","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"88","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1073\/pnas.0602468103","article-title":"A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer","volume":"103","author":"Spector","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"89","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","volume":"30","author":"Parra","year":"2011","journal-title":"Oncogene"},{"issue":"8","key":"90","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.1018001108","article-title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors","volume":"109","author":"Arteaga","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"91","article-title":"Combining AZD8931, a novel EGFR\/HER2\/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models","author":"Davies","year":"2015","journal-title":"Int J Oncol"},{"issue":"4","key":"92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cytogfr.2006.04.004","article-title":"Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases","volume":"17","author":"Dahlback","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"17","key":"93","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Gilmer","year":"2009","journal-title":"Cancer Res"},{"issue":"26","key":"94","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1073\/pnas.0603948103","article-title":"Phosphoproteomic analysis of Her2\/neu signaling and inhibition","volume":"103","author":"Cole","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"95","article-title":"Induction of erbB3\/EGFR heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line","author":"Robert","year":"2007","journal-title":"AACR-NCI-EORTC International Conference (San Francisco, CA)"},{"key":"96","article-title":"miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation","author":"Ma","year":"2015","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"97","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"Hannon","year":"2004","journal-title":"Nat Rev Genet"},{"key":"98","volume-title":"AACR Annual Meeting 2014","author":"Arteaga","year":"2014"},{"issue":"19","key":"99","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Olsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"collaborators","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"101","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody-drug conjugates","volume":"255","author":"Goldmacher","year":"2007","journal-title":"Cancer Lett"},{"issue":"2","key":"102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Isola","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"2","key":"103","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy","volume":"20","author":"Fang","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5060","key":"104","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.256.5060.1205","article-title":"Identification of heregulin, a specific activator of p185erbB2","volume":"256","author":"Lewis","year":"1992","journal-title":"Science"},{"issue":"15","key":"105","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Hynes","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"106","volume-title":"ESMO","author":"Aftimos","year":"2015"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T07:30:42Z","timestamp":1748763042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,27]]},"references-count":106,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2016,9,27]]}},"alternative-id":["7043","26824988"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7043","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,27]]}}}